首页 | 本学科首页   官方微博 | 高级检索  
检索        

利用MHC-I/肽结合的预测与免疫学实验相结合的方法鉴定肿瘤抗原表位
引用本文:李清扬,胡伟,宋婵婵,李亮平.利用MHC-I/肽结合的预测与免疫学实验相结合的方法鉴定肿瘤抗原表位[J].中国病理生理杂志,2019,35(4):584-591.
作者姓名:李清扬  胡伟  宋婵婵  李亮平
作者单位:暨南大学附属第一医院临床肿瘤研究所, 广东 广州 510630
基金项目:国家自然科学基金资助项目(No.81472824);国家重点研发计划(No.2016YFC1303404);广东省科技计划项目(No.2015A020211009);广州市科技计划项目(No.201604020133)
摘    要:目的:建立中国人群常见的人类白细胞抗原(HLA)分子限定的肿瘤抗原免疫表位的鉴定技术,为分离及鉴定肿瘤特异性T细胞以及克隆肿瘤抗原特异性T细胞受体基因提供实验基础。方法:以肿瘤/睾丸抗原NY-ESO、MAGE-A1和KK-LC-1作为模型,选用中国人群常见的HLA-I分型,利用主要组织相容性复合体(MHC)/肽预测软件对这3个抗原的MHC-I类表位进行预测。用PCR技术测定健康志愿者的HLA分型,以志愿者含有的中国人群常见HLA-A*11:01和HLA-B*46:01分型选择预测的抗原表位,设计合成KK-LC-1长肽,进行T细胞刺激实验,用ELISPOT和流式细胞仪分析产生干扰素γ(IFN-γ)的T细胞数量和CD137上调反应,以验证肽对T细胞特异性刺激的有效性。对其中一个反应最好的KK-LC-1长肽,开展短肽的验证。结果:(1)3个肿瘤/睾丸抗原在我国人群35种常见HLA分型中存在众多的强结合表位,在不同蛋白质的序列中分布不均匀;(2)KK-LC-1长肽可刺激T细胞产生T细胞活化反应,即释放IFN-γ和T细胞上调CD137分子,与预测的HLA分型基本吻合;(3)KK-LC-1短肽比长肽刺激效果更好,有更精确的抗原表位。结论:利用MHC/肽预测法并结合抗原特异性刺激实验可快速鉴定肿瘤抗原的T细胞表位;根据长肽的结果缩短肽段,可确定抗原表位。本研究为快速确定肿瘤抗原表位提供了新的途径。

关 键 词:免疫治疗  肿瘤抗原  人类白细胞抗原  主要组织相容性复合体  T细胞受体
收稿时间:2019-01-04

Identification of tumor antigen epitopes by MHC-I/peptide binding prediction and immunological experiments
LI Qing-yang,HU Wei,SONG Chan-chan,LI Liang-ping.Identification of tumor antigen epitopes by MHC-I/peptide binding prediction and immunological experiments[J].Chinese Journal of Pathophysiology,2019,35(4):584-591.
Authors:LI Qing-yang  HU Wei  SONG Chan-chan  LI Liang-ping
Institution:Institute of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China
Abstract:AIM:To establish the methods to identify immune epitopes of tumor antigens restricted by human leukocyte antigen (HLA) alleles frequent in the Chinese population for the isolation and identification of tumor-specific T cells and the cloning of tumor antigen-specific T-cell receptor gene. METHODS:Three cancer/testis antigens NY-ESO,MAGE-A1 and KK-LC-1 were selected as the model antigens to predict the MHC-I binding peptides by major histocompatibility complex (MHC)-peptide binding prediction software. The HLA alleles of healthy volunteers were determined by PCR. The predicted epitopes restricted by HLA-A*11:01 and HLA-B*46:01 of the volunteers were selected for the long peptide design. ELISPOT and flow cytometry were used to analyze the interferon-γ (IFN-γ) spots of the activated T-cells and the up-regulation of CD137 to verify the effectiveness of peptides for T-cell-specific stimulation. We selected long peptides with the best response to verify short peptides. RESULTS:Three cancer/testis antigens containing many strong binding epitopes restricted by 35 HLA alleles common in Chinese population were found. It was found that the predicted epitopes were not equally distributed in the protein sequences. KK-LC-1 antigen was selected for further study. The 2 long peptides stimulated T-cell activation:the release of IFN-γ and up-regulation of CD137 molecules by T cells of the volunteers with the matched HLA alleles. The short peptides worked better than the long peptides.CONCLUSION:Tumor antigen epitopes are quickly identified by MHC/peptide binding prediction and T-cell stimulation analysis. According to the reaction of the long peptide, the short peptide is synthesized to verify the precise epitope. This study provides a new way to determine tumor antigen epitopes quickly.
Keywords:Immunotherapy  Tumor antigen  human leukocyte antigen  Major histocompatibility complex  T-cell receptor
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号